Key Highlights

  • Shares trading down 0.38% to $15.57 in today's session.
  • Trading Volume reached 409.17 thousand shares.
  • The company reported an EPS of negative $3.10.
  • The trial targets relapsed or refractory acute myeloid leukemia, a disease with no approved immunotherapies.

First Patient Dosed in Potentially Registrational Study

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company developing T cell engager therapies, dosed its first patient in a potentially registrational Phase 2 study of CLN-049, an experimental treatment targeting FLT3-expressing cells in relapsed or refractory acute myeloid leukemia. The disease remains difficult to treat, with no currently approved immunotherapies and five-year survival rates of 10% or lower in the relapsed or refractory setting.

Study Design Follows Positive FDA Meeting

The study follows a successful end-of-Phase 1 meeting with the FDA and incorporates a brief dose-optimization phase before advancing to a single-arm expansion cohort. The company is also starting a separate Phase 1/2 combination study pairing CLN-049 with standard chemotherapy agents in newly diagnosed patients.

Shares Essentially Flat Despite Pipeline Milestone

Shares were little changed today, with an EPS of negative $3.10 reflecting the company's continued Investment across its broader immunology and oncology pipeline. The stock continues to trade well below its mid-September level, as the broader healthcare sector has faced pressure from elevated Treasury yields.

Outlook: Dose Escalation Update Expected in December

The company expects to provide an update from its earlier dose escalation study of CLN-049 in December, which may offer additional clarity on the drug's safety and early efficacy profile ahead of further Phase 2 enrollment.